Folate Receptor Targeted Photodynamic Therapy: A Novel Way to Stimulate Anti-Tumor Immune Response in Intraperitoneal Ovarian Cancer
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241411288 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Martha Baydoun und 9 weiteren Autor:innen. Beteiligte Einrichtung: Univ. Lille, Inserm, CHU Lille, U1189-ONCOTHAI-Assisted Laser Therapy and Immunotherapy for Oncology, 59000 Lille, France. Hauptthemen laut MEDLINE: Photochemotherapy, Ovarian Neoplasms, Peritoneal Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: SATT Nord de France.
Abstract (Originalsprache)
Photodynamic therapy (PDT) has shown improvements in cancer treatment and in the induction of a proper anti-tumor immune response. However, current photosensitizers (PS) lack tumor specificity, resulting in reduced efficacy and side effects in patients with intraperitoneal ovarian cancer (OC). In order to target peritoneal metastases of OC, which overexpress folate receptor (FRα) in 80% of cases, we proposed a targeted PDT using a PS coupled with folic acid. Herein, we applied this targeted PDT in an in vivo mouse model of peritoneal ovarian carcinomatosis. The efficacy of the treatment was evaluated in mice without and with human peripheral blood mononuclear cell (PBMC) reconstitution. When mice were reconstituted, using a fractionized PDT protocol led to a significantly higher decrease in the tumor growth than that obtained in the non-reconstituted mice (p = 0.0469). Simultaneously, an immune response was reflected by an increase in NK cells, and both CD4+ and CD8+ T cells were activated. A promotion in cytokines IFNγ and TNFα and an inhibition in cytokines TGFβ, IL-8, and IL-10 was also noticed. Our work showed that a fractionized FRα-targeted PDT protocol is effective for the treatment of OC and goes beyond local induction of tumor cell death, with the promotion of a subsequent anti-tumor response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Univ. Lille, Inserm, CHU Lille, U1189-ONCOTHAI-Assisted Laser Therapy and Immunotherapy for Oncology, 59000 Lille, France.
- Department of Gynecological and Breast Surgery and Oncology, Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière University Hospital, 75013 Paris, France.
- Laboratoire des Réactions et Génie des Procédés (LRGP), CNRS-Université de Lorraine, 1 Rue Grandville, 54000 Nancy, France.
- INSERM UMR9020-UMR-S 1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, 59000 Lille, France.
ORCID-Profile: Henri Azaïs, Céline Frochot
Förderung
- SATT Nord de France
Zitieren
APA
Baydoun, M., Boidin, L., Leroux, B., Vignion-Dewalle, A. S., Quilbe, A., Grolez, G. P., Azaïs, H., Frochot, C., Moralès, O., & Delhem, N. (2023). Folate Receptor Targeted Photodynamic Therapy: A Novel Way to Stimulate Anti-Tumor Immune Response in Intraperitoneal Ovarian Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241411288
Vancouver
Baydoun M, Boidin L, Leroux B, Vignion-Dewalle AS, Quilbe A, Grolez GP, et al. Folate Receptor Targeted Photodynamic Therapy: A Novel Way to Stimulate Anti-Tumor Immune Response in Intraperitoneal Ovarian Cancer. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241411288
BibTeX
@article{Baydoun2023,
author = {Baydoun, Martha and Boidin, Léa and Leroux, Bertrand and Vignion-Dewalle, Anne-Sophie and Quilbe, Alexandre and Grolez, Guillaume Paul and Azaïs, Henri and Frochot, Céline and Moralès, Olivier and Delhem, Nadira},
title = {Folate Receptor Targeted Photodynamic Therapy: A Novel Way to Stimulate Anti-Tumor Immune Response in Intraperitoneal Ovarian Cancer},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241411288}
}
EUVIMED